logo

Gilead Sciences Inc. (GILD)



Trade GILD now with
  Date
  Headline
9/12/2018 8:32:29 AM Gilead Sciences, Precision BioSciences To Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
9/6/2018 1:03:12 AM Gilead And Galapagos Announce TORTUGA Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint
9/4/2018 4:07:58 PM Gilead Enters Agreement With Trianni For Use Of Trianni Transgenic Human Monoclonal Antibody Discovery Platform
8/28/2018 5:07:51 PM Gilead Sciences Appoints Laura Hamill As EVP, Worldwide Commercial Operations
8/27/2018 6:35:22 AM Kite Says Yescarta Gets EMA For Relapsed Or Refractory DLBCL And PMBCL
8/22/2018 7:02:16 AM Sierra Oncology Acquires Drug Candidate Momelotinib From Gilead Sciences
8/14/2018 5:03:58 PM Gilead Sciences Appoints Gregg Alton As Chief Patient Officer
8/9/2018 4:10:30 PM Alpine Immune Sciences Q2 Loss/share $0.57 Vs. Loss $5.40 Year Ago
8/6/2018 6:11:30 AM Gilead Sciences Says CNDA Approved Genvoya For Treatment Of HIV-1 Infection
7/25/2018 6:55:58 PM Gilead Sciences Inc. (GILD) Has Raised Its 2018 EPS Estimate To 1.50 - 1.60 From 1.41 - 1.51
7/25/2018 4:04:11 PM Gilead Sciences Declares Quarterly Dividend Of $0.57, Payable Sept. 27/ Record Sept. 14